Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Revenio: Not a one-trick pony

REG1VExtensive research15.06.2021, 07.11
Juha Kinnunen, Mikael Rautanen
Discuss
Download report (PDF)

Revenio is known as the global beacon of tonometers but these days the company is a noteworthy challenger in more extensive ophthalmic health technology. Imaging tools (previous CenterVue) play an increasing role in future growth and HOME products, as well as software business offer longer term growth promises. Business is growing very profitably, the market has sound growth drivers, and the products have strong competitive advantages. In addition, the company has an excellent track record of its ability to create value with investments in product development, structural reorganization, and new long-term growth templates

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Read more on company page

Key Estimate Figures08.06.2021

202021e22e
Revenue61.179.3102.5
growth-%23.4 %29.9 %29.2 %
EBIT (adj.)19.227.237.1
EBIT-% (adj.)31.4 %34.3 %36.2 %
EPS (adj.)0.580.821.10
Dividend0.320.400.55
Dividend %0.6 %2.7 %3.7 %
P/E (adj.)86.618.013.5
EV/EBITDA61.513.99.7

Forum discussions

So stories change. Nowadays, there is a strong belief in efficient markets, and every single thing is “priced in”. Benjamin Graham used to talk...
8 hours ago
by Ummon
20
Fun to see such high activity in this thread! Feels like an appropriate place to mention that, with Revenio set to release its Q2 report next...
9 hours ago
by Oscar Matheson
5
In my opinion, in the case of Revenio, one can ask whether even the top management believes in that acquisition since they aren’t buying shares...
21 hours ago
by Mamma94
8
Revenio’s earnings have indeed fallen in 2023, 2024, and 2025. Sure, there have been headwinds from the dollar and such, but the “star stock...
8/22/2026, 4:17 PM
by äspee
12
I find the overall development of Revenio quite interesting, to be honest. Previously, Revenio was seen as such a reliable cash-flow machine...
8/22/2026, 2:54 PM
by Johannes Sippola
28
Actually, you already answered it yourself, but I see the acquisition specifically as the biggest risk. If for one reason or another the anticipated...
8/22/2026, 2:45 PM
by Turnipsi
1
Revenio’s share price has started to head upward again over the last few weeks. The shock following the acquisition has faded. Unfortunately...
8/21/2026, 7:34 PM
by SoftaSijoittaja
11